Sunshine Biopharma Signs an Agreement with a Montreal-based Company to Advance the Development of Adva-27a Anticancer Compound

Rhea-AI Summary

Sunshine Biopharma Inc. (OTC PINK:SBFM) has entered into a collaboration agreement with a Montreal-based company to advance its anticancer compound, Adva-27a. This partnership aims to develop chemical synthesis procedures and test the compound on various cancer cells. Following successful cell culture tests, mice studies will be conducted to prepare for clinical trials targeting Stage IV pancreatic cancer at McGill University’s Jewish General Hospital in Montreal. Adva-27a has shown effectiveness against multidrug-resistant cancer cells, including those from pancreatic cancer.

Positive

• Collaboration with a Montreal-based company to advance the development of Adva-27a.
• Anticipated clinical trials for Stage IV pancreatic cancer at a reputable hospital.
• Adva-27a has shown effectiveness against multiple types of resistant cancer cells.

Negative

• Risks and uncertainties highlighted in the forward-looking statements.
• Significant expenses incurred without assurance of generating sufficient revenues.
• Potential legal and regulatory risks associated with expanded service offerings.

MONTREAL, QC / ACCESSWIRE / November 18, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into a collaboration agreement with Montreal-based company for the purposes of advancing the development of Sunshine Biopharma's anticancer compound, Adva-27a. The goal of this collaboration is to develop and implement chemical synthesis procedures for Adva-27a and test the resulting material in various types of cancer cells grown in culture. Based on the cell culture results, Sunshine's drug development partner will conduct mice studies in preparation for entry of Adva-27a into clinical trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and will be performed at McGill University's Jewish General Hospital in Montreal, Canada.

"We are delighted to be working with our new Montreal-based partner and their fully integrated team of experts in chemical synthesis, cell culture assays and mice studies," said Camille Sebaaly, CFO of Sunshine Biopharma.

About Sunshine Biopharma and Adva-27a
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements
This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View source version on accesswire.com:
https://www.accesswire.com/617240/Sunshine-Biopharma-Signs-an-Agreement-with-a-Montreal-based-Company-to-Advance-the-Development-of-Adva-27a-Anticancer-Compound

FAQ

What is the goal of Sunshine Biopharma's collaboration agreement?

The collaboration aims to advance the development of Adva-27a, focusing on chemical synthesis and testing against cancer cells.

What type of cancer is Adva-27a targeting in clinical trials?

Adva-27a is targeting Stage IV pancreatic cancer in planned clinical trials.

Where will the clinical trials for Adva-27a be conducted?

The clinical trials for Adva-27a will be conducted at McGill University's Jewish General Hospital in Montreal, Canada.

What has research shown about the effectiveness of Adva-27a?

Research has demonstrated that Adva-27a is effective in destroying multidrug-resistant cancer cells, including pancreatic and lung cancer cells.

What are the risks mentioned in Sunshine Biopharma's press release?

The risks include uncertainties in financial performance, significant expenses without assured revenue, and potential legal and regulatory challenges.